Theravance Biopharma Stock Today
| TBPH Stock | USD 9.92 0.31 3.23% |
Performance2 of 100
| Odds Of DistressLess than 23
|
Theravance Biopharma is trading at 9.92 as of the 16th of April 2024. This is a 3.23% increase since the beginning of the trading day. The stock's open price was 9.61. Theravance Biopharma has about a 23 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Theravance Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of April 2023 and ending today, the 16th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of May 2014 | Category Healthcare | Classification Health Care |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. The company has 48.56 M outstanding shares of which 7.52 M shares are at this time shorted by private and institutional investors with about 21.12 trading days to cover. More on Theravance Biopharma
Moving against Theravance Stock
| 0.72 | GSK | GlaxoSmithKline PLC ADR Financial Report 24th of April 2024 | PairCorr |
| 0.65 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.61 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.58 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.44 | CRL | Charles River Labora Financial Report 9th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 13th of May 2024
Theravance Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Theravance Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Theravance Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Rick Winningham | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Health Care, NASDAQ Composite, NASDAQ Composite Total, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Theravance Biopharma report their recommendations after researching Theravance Biopharma's financial statements, talking to executives and customers, or listening in on Theravance Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Theravance Biopharma. The Theravance consensus assessment is calculated by taking the average forecast from all of the analysts covering Theravance Biopharma. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Theravance Biopharma's financial statements, Theravance Biopharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Theravance Biopharma is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Theravance Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Theravance Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Theravance Biopharma's financial leverage. It provides some insight into what part of Theravance Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Theravance Biopharma (TBPH) is traded on NASDAQ Exchange in USA. It is located in 901 Gateway Boulevard, South San Francisco, CA, United States, 94080 and employs 99 people. Theravance Biopharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 466.66 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Theravance Biopharma's market, we take the total number of its shares issued and multiply it by Theravance Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Theravance Biopharma conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 48.56 M outstanding shares of which 7.52 M shares are at this time shorted by private and institutional investors with about 21.12 trading days to cover.
Theravance Biopharma currently holds about 132.85 M in cash with (27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74.
Check Theravance Biopharma Probability Of Bankruptcy
Ownership AllocationTheravance Biopharma maintains a total of 48.56 Million outstanding shares. The majority of Theravance Biopharma outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Theravance Biopharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Theravance Biopharma. Please pay attention to any change in the institutional holdings of Theravance Biopharma as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Theravance Ownership Details
Theravance Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of Theravance Biopharma jumping above the current price in 90 days from now is nearly 4.99%. The Theravance Biopharma probability density function shows the probability of Theravance Biopharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Theravance Biopharma has a beta of 0.2. This usually implies as returns on the market go up, Theravance Biopharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Theravance Biopharma will be expected to be much smaller as well. Additionally, theravance Biopharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Theravance Biopharma to move above the current price in 90 days from now is nearly 4.99 (This Theravance Biopharma probability density function shows the probability of Theravance Stock to fall within a particular range of prices over 90 days) .
Theravance Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Theravance Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Theravance Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Theravance Biopharma's value.| Instituion | Recorded On | Shares | |
| Park West Asset Management Llc | 2023-12-31 | 900 K | |
| D. E. Shaw & Co Lp | 2023-09-30 | 689.6 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 572.6 K | |
| Bank Of America Corp | 2023-12-31 | 562.5 K | |
| Northern Trust Corp | 2023-12-31 | 521.9 K | |
| Jacobs Levy Equity Management, Inc. | 2023-09-30 | 407.5 K | |
| Jane Street Group, Llc | 2023-12-31 | 371.5 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 314 K | |
| Chescapmanager Llc | 2023-09-30 | 287.3 K | |
| Weiss Asset Management Lp | 2023-12-31 | 7.5 M | |
| Baupost Group Llc | 2023-12-31 | 7.4 M |
Theravance Biopharma Historical Income Statement
Theravance Biopharma Income Statement is one of the three primary financial statements used for reporting Theravance's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Theravance Biopharma revenue and expense. Theravance Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Theravance Biopharma's Income Tax Expense is increasing as compared to previous years. The Theravance Biopharma's current Tax Provision is estimated to increase to about 2.5 M, while Depreciation And Amortization is projected to decrease to under 4 M. View More FundamentalsTheravance Stock Against Markets
Picking the right benchmark for Theravance Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Theravance Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Theravance Biopharma is critical whether you are bullish or bearish towards Theravance Biopharma at a given time. Please also check how Theravance Biopharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Theravance Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Theravance Biopharma Corporate Directors
Theravance Biopharma corporate directors refer to members of a Theravance Biopharma board of directors. The board of directors generally takes responsibility for the Theravance Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Theravance Biopharma's board members must vote for the resolution. The Theravance Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| William Young | Director | Profile | |
| Donal OConnor | Independent Director | Profile | |
| George Whitesides | Director | Profile | |
| Laurie Alsup | Independent Director | Profile |
How to buy Theravance Stock?
Before investing in Theravance Biopharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Theravance Biopharma. To buy Theravance Biopharma stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Theravance Biopharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Theravance Biopharma stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Theravance Biopharma stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Theravance Biopharma stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Theravance Biopharma, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Theravance Stock please use our How to Invest in Theravance Biopharma guide.
Already Invested in Theravance Biopharma?
The danger of trading Theravance Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Theravance Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Theravance Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Theravance Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Revenue Per Share 1.038 | Quarterly Revenue Growth 0.199 | Return On Assets (0.07) | Return On Equity (0.17) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.